KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Other financing activities: 2012-2022

Historic Other financing activities for Sarepta Therapeutics (SRPT) over the last 1 years, with Dec 2022 value amounting to $554,000.

  • Sarepta Therapeutics' Other financing activities fell 61.31% to $554,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $6.9 million, marking a year-over-year decrease of 4.65%. This contributed to the annual value of $716,000 for FY2022, which is 50.00% down from last year.
  • According to the latest figures from Q4 2022, Sarepta Therapeutics' Other financing activities is $554,000, which was down 61.31% from $1.4 million recorded in Q4 2021.
  • In the past 5 years, Sarepta Therapeutics' Other financing activities registered a high of $5.8 million during Q2 2018, and its lowest value of $554,000 during Q4 2022.
  • For the 2-year period, Sarepta Therapeutics' Other financing activities averaged around $1.1 million, with its median value being $1.4 million (2021).
  • As far as peak fluctuations go, Sarepta Therapeutics' Other financing activities climbed by 4.39% in 2019, and later slumped by 61.31% in 2022.
  • Quarterly analysis of 4 years shows Sarepta Therapeutics' Other financing activities stood at $3.3 million in 2018, then grew by 4.39% to $3.4 million in 2019, then reached $1.4 million in 2021, then slumped by 61.31% to $554,000 in 2022.
  • Its Other financing activities was $554,000 in Q4 2022, compared to $1.4 million in Q4 2021 and $1.4 million in Q2 2021.